A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
Public ClinicalTrials.gov record NCT00504270. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will investigate the safety, efficacy and pharmacokinetics of R3421 in patients with moderate to severe chronic plaque psoriasis. Patients will be randomized to one of 3 treatment groups to receive once daily oral treatment with a)R3421 20mg, b)R3421 120mg, or c)placebo. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.
Study identification
- NCT ID
- NCT00504270
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 66 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2007
- Primary completion
- Aug 31, 2009
- Completion
- Aug 31, 2009
- Last update posted
- Nov 1, 2016
2007 – 2009
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Hot Springs | Arkansas | 71913 | — |
| Not listed | Little Rock | Arkansas | 72205 | — |
| Not listed | Santa Monica | California | 90404 | — |
| Not listed | Alpharetta | Georgia | 30005 | — |
| Not listed | East Windsor | New Jersey | 08520 | — |
| Not listed | Albuquerque | New Mexico | 87106 | — |
| Not listed | New York | New York | 10016 | — |
| Not listed | New York | New York | 10029 | — |
| Not listed | Stony Brook | New York | 11790 | — |
| Not listed | Winston-Salem | North Carolina | 27157 | — |
| Not listed | Providence | Rhode Island | 02903 | — |
| Not listed | Nashville | Tennessee | 37215 | — |
| Not listed | Galveston | Texas | 77550 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Webster | Texas | 77598 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00504270, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2016 · Synced Sep 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00504270 live on ClinicalTrials.gov.